NCT05186753 2026-03-04(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisCogent Biosciences, Inc.Phase 2 Active not recruiting237 enrolled
NCT05024045 2026-03-03Study of Oral LOXO-338 in Patients With Advanced Blood CancersEli Lilly and CompanyPhase 1 Active not recruiting316 enrolled
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 3 FDA